创新价值凸显，中国力量加速渗透，生物医药ETF（512290）连续4日迎净流入

Core Insights - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization and global layout" [1] - The core support for this transition includes population and domestic demand base, as well as comprehensive manufacturing capabilities across the entire industry chain [1] - Companies are actively exploring diversified overseas expansion paths in response to global competition and deepening policies [1] Industry Strategy - The industry needs to "focus on domestic markets, lead with innovation, and expand internationally" [1] - There is an emphasis on strengthening supply chain security and compliance capabilities domestically [1] - Internationally, the focus is on deepening diversified overseas layouts [1] Future Outlook - By 2026, the industry aims to capitalize on opportunities arising from innovation commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1] Investment Vehicle - The Biopharmaceutical ETF (512290) tracks the CS Biopharmaceutical Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets [1] - This index reflects the overall performance of listed companies related to the biopharmaceutical sector [1]